$54.84
0.140.26%
At Close: -
$54.84
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Cytokinetics
CYTKNASDAQ
Cytokinetics (NASDAQ:CYTK) Stock, Analyst Ratings, Price Targets, Predictions
Cytokinetics Inc has a consensus price target of $72.88, established from looking at the 95 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, HC Wainwright & Co., and B. Riley Securities on June 24, 2024, June 17, 2024, and June 4, 2024. With an average price target of $82.33 between JP Morgan, HC Wainwright & Co., and B. Riley Securities, there's an implied 50.13% upside for Cytokinetics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
HC Wainwright & Co.
B. Riley Securities
JMP Securities
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Cytokinetics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/24/2024 | Buy Now | 18.53% | JP Morgan | Tessa Romero | $77 → $65 | Maintains | Overweight | Get Alert |
| 06/17/2024 | Buy Now | 64.11% | HC Wainwright & Co. | Joseph Pantginis | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | 67.76% | B. Riley Securities | Mayank Mamtani | $122 → $92 | Maintains | Buy | Get Alert |
| 05/31/2024 | Buy Now | 42.23% | JMP Securities | Jason Butler | $78 → $78 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/29/2024 | Buy Now | 27.64% | Truist Securities | Srikripa Devarakonda | $86 → $70 | Maintains | Buy | Get Alert |
| 05/28/2024 | Buy Now | 42.23% | JMP Securities | Jason Butler | $106 → $78 | Maintains | Market Outperform | Get Alert |
| 05/23/2024 | Buy Now | 64.11% | HC Wainwright & Co. | Joseph Pantginis | $94 → $90 | Maintains | Buy | Get Alert |
| 05/23/2024 | Buy Now | 9.41% | B of A Securities | Jason Zemansky | $70 → $60 | Maintains | Neutral | Get Alert |
| 05/23/2024 | Buy Now | 73.23% | Barclays | Carter Gould | $100 → $95 | Maintains | Overweight | Get Alert |
| 05/23/2024 | Buy Now | 27.64% | Raymond James | Sean McCutcheon | $92 → $70 | Maintains | Outperform | Get Alert |
| 05/23/2024 | Buy Now | 31.29% | Needham | Serge Belanger | $108 → $72 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 93.29% | JMP Securities | Jason Butler | → $106 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/14/2024 | Buy Now | 71.41% | HC Wainwright & Co. | Joseph Pantginis | → $94 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 96.94% | Needham | Serge Belanger | → $108 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 71.41% | HC Wainwright & Co. | Joseph Pantginis | → $94 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 96.94% | Needham | Serge Belanger | → $108 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 93.29% | JMP Securities | Jason Butler | $110 → $106 | Maintains | Market Outperform | Get Alert |
| 05/09/2024 | Buy Now | 93.29% | Oppenheimer | Justin Kim | $107 → $106 | Maintains | Outperform | Get Alert |
| 05/08/2024 | Buy Now | 71.41% | HC Wainwright & Co. | Joseph Pantginis | → $94 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 96.94% | Needham | Serge Belanger | → $108 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2024 | Buy Now | 56.82% | Truist Securities | Srikripa Devarakonda | $86 → $86 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | Buy Now | 40.41% | JP Morgan | Tessa Romero | $78 → $77 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 80.53% | Mizuho | Salim Syed | $103 → $99 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 95.11% | Oppenheimer | Justin Kim | → $107 | Reiterates | Outperform → Outperform | Get Alert |
| 02/28/2024 | Buy Now | 71.41% | HC Wainwright & Co. | Joseph Pantginis | → $94 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 96.94% | Needham | Serge Belanger | → $108 | Reiterates | Buy → Buy | Get Alert |
| 01/24/2024 | Buy Now | 67.76% | UBS | Ashwani Verma | $61 → $92 | Downgrade | Buy → Neutral | Get Alert |
| 01/22/2024 | Buy Now | 87.82% | Mizuho | Salim Syed | $80 → $103 | Maintains | Buy | Get Alert |
| 01/05/2024 | Buy Now | 64.11% | Morgan Stanley | Jeffrey Hung | $60 → $90 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/28/2023 | Buy Now | 56.82% | Truist Securities | Srikripa Devarakonda | $60 → $86 | Maintains | Buy | Get Alert |
| 12/28/2023 | Buy Now | 67.76% | Raymond James | Sean McCutcheon | $63 → $92 | Maintains | Outperform | Get Alert |
| 12/27/2023 | Buy Now | 96.94% | Needham | Serge Belanger | $60 → $108 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | 71.41% | HC Wainwright & Co. | Joseph Pantginis | $58 → $94 | Maintains | Buy | Get Alert |
| 11/09/2023 | Buy Now | -8.83% | Goldman Sachs | Paul Choi | → $50 | Initiates | → Buy | Get Alert |
| 11/07/2023 | Buy Now | 20.35% | B. Riley Securities | Mayank Mamtani | → $66 | Initiates | → Buy | Get Alert |
| 11/01/2023 | Buy Now | 5.76% | HC Wainwright & Co. | Joseph Pantginis | → $58 | Reiterates | Buy → Buy | Get Alert |
| 10/20/2023 | Buy Now | 5.76% | HC Wainwright & Co. | Joseph Pantginis | $49 → $58 | Maintains | Buy | Get Alert |
| 10/20/2023 | Buy Now | 9.41% | Needham | Serge Belanger | → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/09/2023 | Buy Now | 18.53% | Cantor Fitzgerald | Charles Duncan | $59 → $65 | Maintains | Overweight | Get Alert |
| 10/09/2023 | Buy Now | 29.47% | JMP Securities | Jason Butler | → $71 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/22/2023 | Buy Now | 7.59% | Cantor Fitzgerald | Charles Duncan | → $59 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2023 | Buy Now | 5.76% | SVB Leerink | Roanna Ruiz | → $58 | Initiates | → Outperform | Get Alert |
| 08/04/2023 | Buy Now | 9.41% | Needham | Serge Belanger | → $60 | Reiterates | → Buy | Get Alert |
| 08/04/2023 | Buy Now | 9.41% | Morgan Stanley | Jeffrey Hung | $60 → $60 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | -10.65% | HC Wainwright & Co. | Joseph Pantginis | → $49 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | Buy Now | 9.41% | Morgan Stanley | Jeffrey Hung | → $60 | Reiterates | → Overweight | Get Alert |
| 06/20/2023 | Buy Now | -10.65% | HC Wainwright & Co. | Joseph Pantginis | → $49 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | 29.47% | JMP Securities | Jason Butler | $71 → $71 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/22/2023 | Buy Now | -10.65% | HC Wainwright & Co. | Joseph Pantginis | → $49 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | -1.53% | Oppenheimer | Justin Kim | → $54 | Reiterates | Outperform → Outperform | Get Alert |
| 05/05/2023 | Buy Now | -3.36% | Goldman Sachs | Madhu Kumar | $48 → $53 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 29.47% | JMP Securities | Jason Butler | → $71 | Reiterates | → Market Outperform | Get Alert |
| 05/05/2023 | Buy Now | -10.65% | HC Wainwright & Co. | Joseph Pantginis | → $49 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 9.41% | Needham | Serge Belanger | → $60 | Reiterates | → Buy | Get Alert |
| 04/03/2023 | Buy Now | 7.59% | Cantor Fitzgerald | Charles Duncan | $61 → $59 | Maintains | Overweight | Get Alert |
| 04/03/2023 | Buy Now | 11.23% | UBS | Ashwani Verma | $67 → $61 | Maintains | Buy | Get Alert |
| 03/31/2023 | Buy Now | -10.65% | HC Wainwright & Co. | Joseph Pantginis | $56 → $49 | Maintains | Buy | Get Alert |
| 03/20/2023 | Buy Now | -5.18% | JP Morgan | Tessa Romero | $55 → $52 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 11.23% | Cantor Fitzgerald | Charles Duncan | → $61 | Reiterates | → Overweight | Get Alert |
| 03/07/2023 | Buy Now | 29.47% | JMP Securities | Jason Butler | → $71 | Reiterates | → Market Outperform | Get Alert |
| 03/06/2023 | Buy Now | 29.47% | JMP Securities | Jason Bazinet | → $71 | Reiterates | → Market Perform | Get Alert |
| 03/06/2023 | Buy Now | 9.41% | Needham | Serge Belanger | → $60 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | -12.47% | Goldman Sachs | Madhu Kumar | $56 → $48 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 29.47% | JMP Securities | Jason Butler | → $71 | Reiterates | → Market Perform | Get Alert |
| 03/02/2023 | Buy Now | 9.41% | Needham | Serge Belanger | $58 → $60 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | -1.53% | Oppenheimer | Justin Kim | $55 → $54 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 5.76% | Needham | Serge Belanger | → $58 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | Buy Now | -10.65% | B of A Securities | Jason Zemansky | → $49 | Initiates | → Neutral | Get Alert |
| 01/17/2023 | Buy Now | 2.12% | Goldman Sachs | Madhu Kumar | $47 → $56 | Maintains | Buy | Get Alert |
| 12/23/2022 | Buy Now | 5.76% | Needham | Serge Belanger | $60 → $58 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | 9.41% | Truist Securities | Srikripa Devarakonda | → $60 | Initiates | → Buy | Get Alert |
| 12/15/2022 | Buy Now | 20.35% | UBS | Ashwani Verma | $80 → $66 | Maintains | Neutral | Get Alert |
| 12/15/2022 | Buy Now | -14.3% | Goldman Sachs | Madhu Kumar | $55 → $47 | Maintains | Buy | Get Alert |
| 12/15/2022 | Buy Now | 2.12% | HC Wainwright & Co. | Joseph Pantginis | $29 → $56 | Maintains | Buy | Get Alert |
| 12/14/2022 | Buy Now | 29.47% | JMP Securities | Jason Butler | $82 → $71 | Maintains | Market Outperform | Get Alert |
| 10/11/2022 | Buy Now | 45.88% | UBS | Ashwani Verma | → $80 | Initiates | → Buy | Get Alert |
| 10/03/2022 | Buy Now | 49.53% | JMP Securities | Jason Butler | $53 → $82 | Maintains | Market Outperform | Get Alert |
| 08/05/2022 | Buy Now | 14.88% | Raymond James | Dane Leone | $54 → $63 | Maintains | Outperform | Get Alert |
| 07/15/2022 | Buy Now | 9.41% | Morgan Stanley | Jeffrey Hung | $46 → $60 | Maintains | Overweight | Get Alert |
| 06/10/2022 | Buy Now | 31.29% | Piper Sandler | Yasmeen Rahimi | $50 → $72 | Maintains | Overweight | Get Alert |
| 05/24/2022 | Buy Now | 3.94% | Goldman Sachs | Graig Suvannavejh | $71 → $57 | Maintains | Buy | Get Alert |
| 05/16/2022 | Buy Now | 45.88% | Mizuho | Salim Syed | $54 → $80 | Maintains | Buy | Get Alert |
| 05/05/2022 | Buy Now | 9.41% | Needham | Serge Belanger | $52 → $60 | Maintains | Buy | Get Alert |
| 04/29/2022 | Buy Now | 36.76% | HC Wainwright & Co. | Joseph Pantginis | $69 → $75 | Maintains | Buy | Get Alert |
| 12/22/2021 | Buy Now | 0.29% | Oppenheimer | Justin Kim | → $55 | Initiates | → Outperform | Get Alert |
| 12/21/2021 | Buy Now | 25.82% | HC Wainwright & Co. | Joseph Pantginis | $62 → $69 | Maintains | Buy | Get Alert |
| 12/10/2021 | Buy Now | 5.76% | JP Morgan | Anupam Rama | — | Initiates | → Overweight | Get Alert |
| 12/01/2021 | Buy Now | -1.53% | Mizuho | Salim Syed | — | Maintains | Buy | Get Alert |
| 11/04/2021 | Buy Now | 13.06% | HC Wainwright & Co. | Joseph Pantginis | $58 → $62 | Maintains | Buy | Get Alert |
| 10/08/2021 | Buy Now | -17.94% | Morgan Stanley | Jeffrey Hung | — | Maintains | Overweight | Get Alert |
| 10/07/2021 | Buy Now | 36.76% | Jefferies | Akash Tewari | — | Initiates | → Buy | Get Alert |
| 08/06/2021 | Buy Now | 5.76% | HC Wainwright & Co. | Joseph Pantginis | $53 → $58 | Maintains | Buy | Get Alert |
| 07/20/2021 | Buy Now | -27.06% | Barclays | Carter Gould | — | Maintains | Overweight | Get Alert |
| 07/19/2021 | Buy Now | -3.36% | HC Wainwright & Co. | Joseph Pantginis | $41 → $53 | Maintains | Buy | Get Alert |
| 07/19/2021 | Buy Now | -12.47% | Needham | Chad Messer | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Cytokinetics (CYTK) stock?
The latest price target for Cytokinetics (NASDAQ:CYTK) was reported by JP Morgan on June 24, 2024. The analyst firm set a price target for $65.00 expecting CYTK to rise to within 12 months (a possible 18.53% upside). 45 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cytokinetics (CYTK)?
The latest analyst rating for Cytokinetics (NASDAQ:CYTK) was provided by JP Morgan, and Cytokinetics maintained their overweight rating.
When was the last upgrade for Cytokinetics (CYTK)?
There is no last upgrade for Cytokinetics
When was the last downgrade for Cytokinetics (CYTK)?
The last downgrade for Cytokinetics Inc happened on January 24, 2024 when UBS changed their price target from $61 to $92 for Cytokinetics Inc.
When is the next analyst rating going to be posted or updated for Cytokinetics (CYTK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytokinetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytokinetics was filed on June 24, 2024 so you should expect the next rating to be made available sometime around June 24, 2025.
Is the Analyst Rating Cytokinetics (CYTK) correct?
While ratings are subjective and will change, the latest Cytokinetics (CYTK) rating was a maintained with a price target of $77.00 to $65.00. The current price Cytokinetics (CYTK) is trading at is $54.84, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.